CA-ANDERSEN-GLOBAL
6.4.2022 12:40:12 CEST | Business Wire | Pressemeddelelse
Andersen Global fortsætter med at styrke sin latinamerikanske platform, nu hvor skatterådgivningsfirmaet SKATT bliver den seneste medlemsvirksomhed i Mexico, der tilslutter sig den globale organisation. SKATT, som har været en samarbejdende virksomhed siden 2020, udvider organisationens eksisterende skattemæssige og juridiske kompetencer i regionen sammen med medlemsvirksomheden Andersen i Mexico.
Under ledelse af administrerende direktør Jaime Rojas tilbyder SKATT en række skræddersyede skattetjenester, herunder arbejde med international skat, procesførelse, udenrigshandel og told samt interne afregningspriser. Virksomheden anerkendes konsekvent af Leaders League , ITR World Tax og World Transfer Pricing , og opererer med fagfolk i Mexico City, Guadalajara og Queretaro.
“Ved at blive medlem af Andersen Global, vil vi være i stand til at udvide vores rækkevidde og levere problemfri kvalitetsservice og dertil globale kompetencer”, udtaler administrerende direktør Jaime Rojas. “Vores virksomhed er vokset enormt i løbet af de sidste par år, og det at arbejde sideløbende med Andersen Global viser vores engagement i vores kunder, alt imens vi stræber efter at være en benchmark-organisation.”
Andersen Globals bestyrelsesformand og administrerende direktør Mark Vorsatz tilføjer: “Teamet hos SKATT har arbejdet problemfrit med fagfolkene fra vores medlemsvirksomheder og samarbejdende virksomheder i regionen. At SKATT er blevet tilføjet som medlemsvirksomhed føjer dybde til vores ressourcer i regionen, mens vi fortsat fokuserer på at give kunderne omfattende dækning og service i Latinamerika og globalt.”
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsvirksomheder, bestående af skatte- og juraeksperter over hele verden. Andersen Global blev stiftet af den amerikanske medlemsvirksomhed Andersen Tax LLC har Andersen Global i 2013 og har nu over 10.000 fagfolk globalt og er repræsenteret på mere end 336 lokaliteter via sine medlemsvirksomheder og samarbejdende virksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220405005359/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 20266.7.2026 13:30:00 CEST | Press release
Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% three-year overall survival, and a survival curve plateau beyond two yearsData presented in a heavily pretreated population where durable long-term survival is rarely reported17% of patients alive and off all systemic anticancer therapy at last follow-upExtended safety follow-up showed no new safety signals, no treatment-related deaths, and 98% resolution of immune-mediated diarrhea/colitis Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers (E
LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 11:12:00 CEST | Press release
New assessment and risk assurance framework helps enterprises gain unified visibility, prioritise remediation and scale AI securely LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 10:00:00 CEST | Press release
Globally, people are united in their top personal worries: Financial and health issues rank at the top in 2026, averaging 13 percentage points ahead of other concerns.Financial pressure is prominent across Europe, rising in France, Germany, and U.K., and emerging as a top concern in newly measured markets, Spain and Switzerland.Allianz published these results in “The Allianz 3am Report 2026,” which surveyed 10,000 people across 10 countries worldwide about what keeps them awake at night.Addressing financial concerns requires accessible, targeted financial and risk education. To support this, Allianz has launched the “Allianz School For Life” learning platform. Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countri
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 08:40:00 CEST | Press release
A long-established Japanese general contractor will contribute construction expertise to advance Fusion Pilot Plant development toward commercially viable fusion power. Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 07:15:00 CEST | Press release
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exitThe proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor typesMyricx Bio's first-in-class NMTi payload platform is designed to improve the therapeutic index of ADCs, offering the potential for more effective and better-tolerated treatment options for cancer patientsThe transaction valued at up to $1.5 billion including $1.1 billion cash upfront Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discove
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum